{
  "docId": "019de076-86c0-778c-b811-8ed1a345f3e4",
  "docSlug": "3a23784462a131093cb118313f70597a",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 25,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Notes at bottom define FPFV and LPO.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/13",
  "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4",
  "deckJsonHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4.json",
  "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.5,
        "y": 0.2
      },
      "kind": "list",
      "text": "Exploring Co-Administration with a DPP4 inhibitor: Identify ability to effectively decreased hepatic inflammation; Explore ability to reduce systemic inflammation and fibrosis biomarkers; Reduced hepatic lipid and collagen deposition in Ob-MASH mice",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5da32c0a-56a9-44d3-a844-887f843a4a5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Support use as a monotherapy: DA-1241 modified the progression of MASH in Ob-MASH mice; Exploring improved biomarkers (CCL2, TNFa, and TIMP1), liver fat content, and stiffness as measured by Fibroscan and MRI",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe56ef43-7c9a-4cc7-908b-c037514031c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "table",
      "text": "Study Overview: A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA-1241 in subjects with presumed non-alcoholic steatohepatitis; Primary Endpoint: ALT change from baseline in alanine transaminase; Study Design: 2 Part study (Part 1: 50mg, 100mg, Placebo; Part 2: 100mg + Sitagliptin, Placebo); No. of Subjects: ~90; Location: ~25 centers in US; Enrollment: FPI Aug 2023, LPLV June 2024",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e7156d4-c547-4660-a87d-88b640454673",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "DA-1241: Ongoing Phase 2a in MASH",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6331a58-9b0b-447b-b990-f602ac9f32e7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "2f1b0f34-7fd6-4a91-ba5d-8e787a1d27d1",
      "evidence": "table/data: Study Overview: A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA-1241 in subjects with presumed non-alcoholic steatohepa",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 13,
      "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}